Bio-Techne (TECH) Q1 2025 Earnings Transcript

Bio-Techne reported Q1 revenue of $289.5 million, up 5% reported and 4% organically, with adjusted EPS of $0.42 versus $0.41 a year ago despite gross margin compression to 69.5% and operating margin decline to 29%. Diagnostics and Spatial Biology was the standout, with revenue up 14% and operating margin improving to 5.1%, while Protein Sciences returned to 1% organic growth and GMP reagents rose over 60%. Management guided Q2 revenue growth to mid-single digits and said margins should improve in the second half as China stimulus, biotech spending, and productivity initiatives support growth.

Analysis

TECH is quietly becoming a better quality compounder even before the end markets fully recover: the mix is shifting toward higher-margin consumables, diagnostics, and workflow pull-through while the company keeps adding operating leverage through productivity. The key second-order effect is that every installed instrument in COMET, Simple Western, and cell therapy workflow tends to create a recurring reagent/service annuity, so the current quarter’s margin pressure is less important than the installed-base expansion rate over the next 6-18 months.

The market is likely underestimating the optionality in cell and gene therapy. Wilson Wolf plus GMP reagents is not just a growth pocket; it is a distribution wedge into late-stage trials and eventual commercial workflows, and the planned full ownership by 2027 should make that economic stream more visible. That said, the near-term risk is lumpy order timing from large accounts, which can create false positives in the quarter-to-quarter data and keep the stock range-bound until broad biotech spend actually converts into sustained run-rate demand.

The contrarian take is that China is not the main driver of the thesis anymore: a modest rebound there helps, but the more important inflection is small-biotech spending and large-pharma budget normalization in 2025. If those recoveries lag, the company can still hold mid-single-digit growth, but the multiple probably won’t expand meaningfully. If they do recover, TECH could move from a defensive quality story to an operating leverage story quickly because the diagnostics/spatial segment is already proving it can scale margins off a much smaller base.

Key Decisions for Investors

• Go long TECH on a 3-6 month horizon; use any post-earnings consolidation as entry. Risk/reward favors upside if biotech spend broadens, with downside cushioned by recurring consumables and high gross margins.
• Pair long TECH vs short a more instrument-heavy life science tools name over the next 1-2 quarters. TECH has better recurring revenue mix and more visible pull-through from installed base growth, while pure capex-exposed peers remain more vulnerable to budget delays.
• Sell put spreads in TECH 3-6 months out if implied volatility stays elevated after earnings. The stock looks likely to drift higher on gradual operating leverage rather than a sharp re-rating, making premium capture attractive.
• Add exposure ahead of 2H25 catalyst windows tied to China stimulus orders and new assay launches. The setup is asymmetric because positive surprises in either vector can expand the multiple, while misses likely only delay the thesis.
• For higher-conviction traders, consider a bull call spread in TECH with 6-9 month expiry. This captures upside from margin recovery and biotech normalization while limiting risk if budget flush and pharma spending recovery stay weak.